While the European off-patent industry has welcomed the latest update to the EU’s industrial strategy, including a detailed analysis of European dependencies on the global API manufacturing network, it has urged the European Commission to go further and provide “tailored actions” to bolster local manufacturing.

A detailed report published by Medicines for Europe setting out policies affecting the off-patent industry across 22 European countries demonstrates the urgent need for pricing and reimbursement and procurement reforms, the association insists.

A “structured dialog” led by the European Commission with pharmaceutical industry stakeholders provides a critical opportunity to address weaknesses in the stability and security of the supply chain by improving the environment for local manufacturing, Medicines for Europe believes.